18 THERAPY Lisinopril hypotensive after acute MI Lisinoprillowers BP after acute myocardial infarction, in doses lower than those normally used for hypenension. However, this does not adversely affect prognosis, according (0 the GISSI-3* investigators. The GISSI-3 pilot study involved 1526 patients with MI receiving standard therapy who were randomised to additionally receive lisinoprii (oral; 2.5-10 mg/day), nitroglycerin (IV then transderma1; adjusted according to BP) or neither treatment, for 3 days starting within 24 hours of symptom onset. Both oral lisinopril and IV nitroglycerin decreased BP in the first 24 hours after MI. comDared with standard treatment. This effect of lisinopril was maintained over the 3 days, while the effect of nitroglycerin was lost when a transderrnal formulation was used from day 2. Usinopril caused more episodes of persistent hypotension, but mortaJity in patients experiencing hypotension was significantly lower among lisinopril recipients compared with the other groups . • Gruppo ltoJiano per 10 Studio della SopruwivenqJ MU'lrifarto MioaurJico-3 LuiDi R. Avanziai F. De Nicolao A, Roo;:cbmi M, GIS51.) lnvestigawn. EfJCCl$ of 1if.iMpri! and nitroglyec:ri.n on blood PJUSun: carly afta" lII}'ocardW inf arction: the G1551·3 pilot swdy. Clinic:a11'barmaoo1ogy and lba;apcutici 680-692, Dec 1994 .... ..... , )00- EdiIorial.:ommenJ: The combinmion of lisinopril and nitroglycerin was subsequently shown to have some benefit in terms of mortality and clinical endpoinu in patients with acute MI in tM GISSI-3 trial, which involved approximately 19000 patients [see Inpharma 914: 4, 20Novl994; 800231865, /npharma 938: 18, 2l May 1994; 800267224, and Inpharma 941: IS, 11 Jun /994; 8OO273306J. 01S6-21O:W5lO913-OOO18tS01.oo" Adle Intemlltlonal Llmbd 11115. All rlgtrt.

Lisinopril hypotensive after acute MI

Download PDF Report

Upload
vudung
View
213
Download
0

Embed Size (px)

Citation preview

18 THERAPY

Lisinopril hypotensive after acute MI

Lisinoprillowers BP after acute myocardial infarction, in doses lower than those normally used for hypenension. However, this does not adversely affect prognosis, according (0 the GISSI-3* investigators.

The GISSI-3 pilot study involved 1526 patients with MI receiving standard therapy who were randomised to additionally receive lisinoprii (oral; 2.5-10 mg/day), nitroglycerin (IV then transderma1; adjusted according to BP) or neither treatment, for 3 days starting within 24 hours of symptom onset.

Both oral lisinopril and IV nitroglycerin decreased BP in the first 24 hours after MI. comDared with standard treatment. This effect of lisinopril was maintained over the 3 days, while the effect of nitroglycerin was lost when a transderrnal formulation was used from day 2. Usinopril caused more episodes of persistent hypotension, but mortaJity in patients experiencing hypotension was significantly lower among lisinopril recipients compared with the other groups . • Gruppo ltoJiano per 10 Studio della SopruwivenqJ MU'lrifarto MioaurJico-3

LuiDi R. Avanziai F. De Nicolao A, Roo;:cbmi M, GIS51.) lnvestigawn. EfJCCl$

of 1if.iMpri! and nitroglyec:ri.n on blood PJUSun: carly afta" lII}'ocardW

infarction: the G1551·3 pilot swdy. Clinic:a11'barmaoo1ogy and lba;apcutici ~6: 680-692, Dec 1994 .... .....,

)00- EdiIorial.:ommenJ: The combinmion of lisinopril and nitroglycerin was subsequently shown to have some benefit in terms of mortality and clinical endpoinu in patients with acute MI in tM GISSI-3 trial, which involved approximately 19000 patients [see Inpharma 914: 4, 20Novl994; 800231865, /npharma 938: 18, 2l May 1994; 800267224, and Inpharma 941: IS, 11 Jun /994; 8OO273306J.

01S6-21O:W5lO913-OOO18tS01.oo" Adle Intemlltlonal Llmbd 11115. All rlgtrt. ~